Navigation Links
Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
Date:1/22/2009

SAN DIEGO, Jan. 22 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a dose-ranging Phase 2b clinical trial to evaluate oral viscous budesonide (OVB) for the treatment of children and adolescents with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. EoE can cause difficulty in swallowing and heartburn, and in severe cases it can lead to food impaction (food getting stuck in the esophagus) and in children, a failure to thrive (poor growth or weight loss). The trial is being conducted at multiple U.S. clinical centers that specialize in the treatment of patients with gastrointestinal diseases.

EoE is an emerging disease that has only recently been classified as a separate condition. Most centers of excellence have seen a dramatic rise in the incidence and diagnosis of EoE over the last decade. EoE tends to be a chronic disease with persistent or relapsing symptoms. The disease occurs when eosinophils, a type of white blood cell involved in allergic reactions, infiltrate the surface of the esophagus. This eosinophil infiltration leads to inflammation of the esophagus and is believed to cause the symptoms of EoE. A variety of stimuli may trigger this allergic process including certain foods and environmental allergens. People with EoE commonly have other allergic conditions such as asthma or eczema.

Symptoms of EoE may include nausea, dysphagia (problems swallowing), vomiting, stomach pain, chest pain, heartburn, loss of weight, and food impaction. Other symptoms may include reflux that does not respond to proton pump inhibitor therapy, failure to thrive, poor appetite, malnutrition and difficulty sleeping.

The double-blind, randomized, placebo-controlled 12-week study in up to 80 patients with confirmed EoE aged two to 18 is designed to evaluate three different doses of OVB. Patients will be evaluated by performing biopsies of the esophagus obtain
'/>"/>

SOURCE Meritage Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
2. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
5. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
6. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
7. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
8. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
9. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
11. Pharmasset Reports Fiscal Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... 14, 2012 Arena Pharmaceuticals, Inc. (NASDAQ: ... quarter and full year ended December 31, 2011, and ... to be an important option for physicians to address ... and improve their overall cardiometabolic health," said Jack Lief, ...
...  Watson Pharmaceuticals, Inc. (NYSE: WPI ) today ... Abbreviated New Drug Application (ANDA) with the U.S. Food ... Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and ... of Forest Laboratories, BYSTOLIC®, which is a beta-adrenergic blocking ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments 8Watson Confirms BYSTOLIC(R) Patent Challenge 2Watson Confirms BYSTOLIC(R) Patent Challenge 3
(Date:1/22/2015)... (PRWEB) January 22, 2015 Carinsurancesavings.biz has released ... accidental death and dismemberment insurance . , Purchasing an ... can be very advantageous. This type of rider provides benefits ... dismemberment can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... Colorado (PRWEB) January 22, 2015 Four years since ... Queen – which coincided with the marriage of Avasa & Matthew ... THE ROAD, which is scheduled for release through White Swan Records ... message that there is a sacred path available to all of ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell ... relapsed chronic lymphocytic leukemia (CLL) or diseases that no ... to the therapy. The results of this study were ... of Clinical Oncology. ,"Chronic lymphocytic leukemia ...
... by U.S firm Schwarz has found to be potential in ... other drugs - the company said on Monday following the ... of the 485-patient study were presented at the North American ... a 200-mg dose of the drug, lacosamide, had 14.4 percent ...
... A new study has challenged the ill-effects of obesity, as ... that being overweight// is a major risk factor for cancer, ... may help in protecting younger women from breast cancer. ... Mass Index results in reduced levels of female hormones, the ...
... the Insecticides Act, 1968 registers pesticides only after satisfying ... data generated under supervised trials is analyzed and used ... of Health & Family Welfare under the Prevention of ... inspection of fruits and vegetables for the presence of ...
... Denis Broun, UNAIDS India coordinator, explained how India’s legal stance ... against HIV/AIDS and is an// infringement of the human rights ... mainly to bring offenders to book, in cases dealing with ... the law is annulled, it may cause a setback to ...
... heart attack Sunday and was taken to a military hospital, ... Pinochet's condition as "serious but stable". ,It said ... were also affected. ,On Nov 25, Pinochet, who ... of supporters gathering outside his home here to congratulate him. ...
Cached Medicine News:
Agility has delivered a RFID-enabled mobile asset management program....
... can provide RFID-enabled tracking and ... medical and surgical supplies. AgileTrac ... track tote deliveries to patient ... track and manage inventories of ...
... RoamAlert Integrity system builds on the ... door controllers in the system are ... a standard Windows® operating system, which ... of a personal computer, RoamAlert Integrity ...
... enterprise visibility solution that allows hospitals ... and increase patient satisfaction. Awarix ... and geospatial visual technologies with your ... real time patient care model that ...
Medicine Products: